Isoray, in collaboration with Viewpoint Molecular Targeting, is a world-class organization dedicated to delivering personalized, targeted therapies for cancer patients. With over a quarter century of experience in the medical technologies market, Isoray focuses on advancing cancer treatments using radiation, radiopharmaceuticals, and imaging technologies. Their goal is to ensure that targeted medical doses are delivered directly to the tumor site while sparing healthy tissues.

Isoray's approach involves developing treatments that are delivered exactly where surgeons want them to be. Through strong partnerships with global medical institutions and pharmaceutical companies, Isoray stays at the forefront of progress and innovation. They utilize radioisotope technology to treat tumors on a cellular level, using proprietary targeting peptides for diagnosis and alpha-particle radiopharmaceuticals for molecular-level attack.

Notably, Isoray manufactures and distributes Cesium-131 brachytherapy radioisotope seeds, which have high energy and a short half-life, enabling patients to resume their daily lives during therapy. Additionally, Isoray is involved in immuno-oncology clinical trials, exploring the combination of Cesium-131 with other therapies to treat difficult cancers. With their theranostic approach, Isoray aims to provide powerful alpha radiation specifically to cancer cells, maximizing efficacy while minimizing toxicity.

Stay updated on Isoray's latest news and advancements by signing up for their newsletter